The combination of the anti-programmed cell death ligand-1 (PD-L1) and anti-vascular endothelial growth factor (VEGF) antibodies atezolizumab and bevacizumab (Atezo + Bev) is a standard of care for patients with untreated unresectable hepatocellular carcinoma (uHCC) based on results of the IMbrave150 trial [1,2]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.